-
Abstract: CROM antigen is a kind of expression in GPI blood group antigen on the cell membrane, is Ⅳ transmembrane protein, also known as the decay accelerating factor(DAF), complement regulatory proteins, and membrane CD55 differentiation antigens. The peptide chain has four ring-folded structures in which all CROM antigens are expressed. The main function of CROM glycoprotein is to regulate the complement system to protect host cells and tissues from damage by controlling the amount of complement C3 and adjusting the amount of inhibiting the production of C5. CROM antigens are polymorphic and missense mutations lead to different antigenicity expressions. CROM antigens can trigger a mild transfusion hemolysis.
-
-
表 1 等位基因与编码的抗原
抗原名 抗原频率 对应抗原 核苷酸 外显子 氨基酸 CROM1 Cra 高频 679G(C) 6 Ala227(Pro) CROM2 Tca 高频 CROM3，CROM4 155G(T或C) 2 Arg52(Leu或Pro) CROM3 Tcb 第频 CROM2，CROM4 155G>T 2 Arg52Leu CROM4 Tcc 第频 CROM2，CROM3 155G>C 2 Arg52Pro CROM5 Dra 高频 596C(T) 5 Ser199(Leu) CROM6 Esa 高频 239T(A) 2 Ile80(Asn) CROM7 IFC 高频 (Various) CROM8 WESa 第频 CROM9 245T>C 2 Leu82Arg CROM9 WESb 高频 CROM8 245T(G) 2 Leu82(Arg) CROM10 UMC 高频 749C(T) 6 Thr250(Met) CROM11 GUTI 高频 719G(T) 6 Arg240(His) CROM12 SERF 高频 647C(T) 5 Pro216(Lys) CROM13 ZENA 高频 725T(G) 6 His242(Gln) CROM14 CROV 高频 466G(A) 3 Gln156(Lys) CROM15 CRAM 高频 740A(G) 6 Gln247(Arg) CROM16 CROZ 高频 389G(A) 3 Arg130(His) CROM17 CRUE 高频 639G(A) 5 Leu217(Trp) CROM18 CRAG 高频 173A(G) 2 Asp58(Gly) CROM19 CROK 高频 CROM20 KCAM 高频 
下载: 导出CSV
表 2 Null表型基因(Inab表型)
基因型 基因名 核苷酸 外显子 氨基酸 CROM：-7或Inab CROM*01N.01 c.261G>A 2 p.Trp87Ter CROM：-7或Inab CROM*01N.02 c.263C>A 2 p.Ser88Ter
下载: 导出CSV
-
[1] Busani S, Ghirardini A, Petrella E, et al. A challenging case of pregnancy with placenta accreta and very rare irregular antibodies versus Cromer blood group system: a case report[J]. J Med Case Rep, 2015, 9: 112. doi: 10.1186/s13256-015-0607-7
[2] Li G, Yin Q, Ji H, et al. A study on screening and antitumor effect of CD55-specific ligand peptide in cervical cancer cells[J]. Drug Des Devel Ther, 2018, 12: 3899-3912. doi: 10.2147/DDDT.S182337
[3] Qiao P, Dang EL, Fang H, et al. Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid[J]. Oncotarget, 2017, 23, 9(85): 35517-35527.
[4] Oyong DA, Kenangalem E, Poespoprodjo JR, et al. Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia[J]. JCI Insight, 2018, 3(22): e124854. doi: 10.1172/jci.insight.124854
[5] Kurolap A, Eshach Adiv, Hershkovitz T, et al. Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency[J]. J Pediatr Gastroenterol Nutr, 2019, 68(3): 325-333. doi: 10.1097/MPG.0000000000002198
[6] Furniss RCD, low WW, Mavridou DAI, et al. Plasma membrane profiling during enterohemorrhagic E. coli infection reveals that the metalloprotease StcE cleaves CD55 from host epithelial surfaces[J]. J Biol Chem, 2018, 293(44): 17188-17199. doi: 10.1074/jbc.RA118.005114
[7] Kawamoto M, Murakami Y, Kinoshita T, et al. Recurrent aseptic meningitis with PIGT mutations: a novel pathogenesis of recurrent meningitis successfully treated by eculizumab[J]. BMJ Case Rep, 2018: bcr2018225910. doi: 10.1136/bcr-2018-225910
[8] Inafuku S, Klokman G, Connor KM, et al. The Alternative Complement System Mediates Cell Death in Retinal Ischemia Reperfusion Injury[J]. Front Mol Neurosci, 2018, 11: 278. doi: 10.3389/fnmol.2018.00278
[9] Dho SH, Kim SY, Chung C, et al. Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer[J]. Sci Rep, 2018, 8(1): 8960. doi: 10.1038/s41598-018-27355-8
[10] Li Y, Parks GD. Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization[J]. Viruses, 2018, 10(5): 215.
[11] Dho SH, Lim JC, Kim LK, et al. Beyond the Role of CD55 as a Complement Component[J]. Immune Netw, 2018, 18(1)e11. doi: 10.4110/in.2018.18.e11
[12] Thielen AJF, van Baarsen IM, Jongsma ML, et al. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research[J]. J Immunol Methods, 2018: 456: 15-22. doi: 10.1016/j.jim.2018.02.004
[13] Kotru M, Sharma R, Pramanik SK, et al. Value of CD16/CD66b/CD45 in comparison to CD55/CD59/CD45 in diagnosis of paroxysmal nocturnal haemoglobinuria: An Indian experience[J]. Indian J Med Res, 2017, 146(3): 362-368.
[14] Angeletti A, Marasà M, Cravedi P. et al. CD55 Deficiency and Protein-Losing Enteropathy[J]. N Engl J Med, 2017, 377(15).
[15] Loniewska-Lwowska A, Koza K. Diminished presentation of complement regulatory protein CD55 on red blood cells from patients with hereditary haemolytic anaemias[J]. Int J Lab Hematol, 2018, 40(2): 128-135. doi: 10.1111/ijlh.12752
[16] Kurolap A, Eshach Adiv O, Hershkovitz T, et al. Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency[J]. J Pediatr Gastroenterol Nutr, 2019, 68(3): 325-333. doi: 10.1097/MPG.0000000000002198
[17] Al-Faris L, Al-Humood S, Behbehani F, et al. Altered Expression Pattern of CD55 and CD59 on Red Blood Cells in Anemia of Chronic Kidney Disease[J]. Med Princ Pract, 2017, 26(6): 516-522. doi: 10.1159/000481823
[18] Geoff Daniels. Human Blood Groups[M]. 3rd. edition, 2012: 427-438.
[19] Marion E. The Blood Group Antigen[M]. FactsBook, 2012: 525-548.
[20] 孙长杰, 王晓宁, 李树中, 等. 红细胞Kidd血型抗原研究现状及进展[J]. 中国实验诊断学, 2020, 24(2): 340-343. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD202002047.htm
[21] 唐新, 李树中, 李中华, 等. Lewis血型抗原研究进展[J]. 临床血液学杂志, 2020, 33(4): 289-296. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=880a3f23-50a0-4dce-ae9f-a9e903cb6875
[22] 卞洁, 李树中. 红细胞血型RAPH抗原研究进展[J]. 临床血液学杂志, 2020, 33(2): 148-150. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=8c431756-b51e-4153-8435-3798ef391d51
[23] 段厚全, 李树中. 红细胞LW血型抗原研究进展[J]. 临床血液学杂志, 2020, 33(6): 435-440. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=f5fa88a5-47e4-4561-aee3-03dc3122bb4c
[24] 方莹, 李树中. 红细胞血型Indian抗原研究进展[J]. 临床血液学杂志, 2020, 33(8): 577-581. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=ea3d135b-7184-4e53-a9c2-9702632956f6
[25] 汪小葛, 李树中, 李中华, 等. 红细胞血型OK抗原研究进展[J]. 临床血液学杂志, 2020, 33(10): 729-732. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=95658660-866d-4c79-82c2-9979b90fa1e5
[26] 陈玲, 李树中, 李中华. 红细胞血型Gerbich抗原研究进展[J]. 临床血液学杂志, 2020, 33(12): 876-882. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=47abcd56-e656-4fd9-b413-42e006bafb69
[27] 张黎雯, 李树中, 田丰, 等. 红细胞血型抗原的最新研究进展[J]. 临床血液学杂志, 2021, 34(2): 135-144. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=c2e48248-2a30-408e-9e53-7264ddf08b5d
-
图(4)
表(2)
计量
- 文章访问数: 954
- PDF下载数: 237
- 施引文献: 0